BrainSpec earns special FDA designation for non-invasive virtual biopsy technology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BrainSpec, the web-based software platform that intends to use existing MRI machines to enable virtual biopsies of the brain, has received FDA designation as a breakthrough device for estimating isocitrate dehydrogenase (IDH) status in glioma patients in whom biopsy is inadvisable.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Foundation Medicine Inc., a pioneer in molecular profiling for cancer, and Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people with life-threatening diseases, has formed a collaboration to develop FoundationOne CDx as a companion diagnostic for Day One’s lead investigational therapy, DAY101 (tovorafenib).

Login